Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Medicare Wastage ‘Refund’ Collections Delayed To ‘Align’ With IRA

Executive Summary

A new Medicare rebate for discarded portions of single-use vials is taking effect as scheduled in January – but the first invoices won’t be issued in the fall as planned. CMS says it wants to wait to ‘align’ the collections process with the new inflation rebates enacted by the IRA.

You may also be interested in...



Medicare Drug Pricing Reform Is A Reality: Here Is What’s On The Agenda

Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.     

US Medicare Wastage ‘Refund’: Wasted Effort?

The upcoming implementation of a new ‘refund’ program for unused drugs included in single-use vials is a remarkable story of a policy idea moving from academic research into the real world. But the actual impact sure has shrunk along the way.

Medicare Rebates On Drug ‘Wastage’: New Products Get Limited Time Reprieve

Regulation from CMS may drive manufacturers to repackage Medicare Part B drugs sold in single-use containers to avoid waste that would be subject to new rebate.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel